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Many chemical agents, drugs, and other
diseases (2) have been implicated in produc-
ing or inciting a fiareup of porphyria in both
man and laboratory animals. Numerous studies
have demonstrated that both clinical and bio-
chemical changes can be induced to present a
picture of porphyria (1, 3—7, 15, 17—19, 22).
The list of inciting drugs and chemical agents
which have been impheated continues to
grow and at present includes barbiturates,
Sedormid®, estrogens, Sulphonal®, Trional®,
Veronal®, alcohol, arsenic, lead, hexaehloroben-
zene, ehloroquine, phenylhydrazine, isopropyl
acetamid, di- and trichlorophenol, D D C, and
griseofulvin (9, 12, 14, 16, 20).
A drug (griseofulvin) reputed to be an in-
citing agent was administered to patients with
porphyria cutanea tarda (PCT) and the clin-
ical manifestations as well as the biochemical
changes of the disease were studied. This
study delineates the variables of skin status,
liver function, and porphyrin metabolism while
griseofulvin was administered to patients with
proven PCT. This drug was chosen because of its
frequent and increasing use in the treatment of
fungal diseases.
A point which cannot be overemphasized is
the type of porphyria being produced or
flared by these agents. There is a commonly
accepted scheme that divides the spectrum of
porphyria into two basic types, one of hemo-
poietie origin with the basic defect stemming
from the bone marrow and the other of hepatic
origin with the defect being the liver cell en-
zyme system, causing an overproduction of pyr-
roles and precursors. The hemopoietie porphy-
rias are of two varieties, congenital erythrocytie
porphyria (Guther, 1911), a rare occurrence
with a grave prognosis, and the recently de-
scribed erythropoietic protoporphyria (21). The
hepatie porphyrias are of 3 well-accepted va-
rieties; acute intermittent porphyria (AlP) pre-
senting with features of acute abdominal pain,
and few, if any, cutaneous findings; mixed
porphyria (Variegata) exhibiting episodes of
abdominal pain and neurologic complications
with varying degrees of cutaneous manifesta-
tions; and porphyria eutanea tarda (PCT).
Porphyria cutanea tarda (PCT), a symptom
complex first given its name by Waldenstrom
in 1937, has several distinguishing charac-
teristics. PCT is to be found in two forms,
hereditary and acquired, but regardless of its
origin there are definite clinical and biochem-
ical features which are consistent. The clinical
signs may include photosensitivity to both nat-
ural and artificial light, vesicles on the light-
exposed areas, specifically the dorsum of the
hands, back of the neck and face, eolloid milia
of these same areas, hypertrichosis (particularly
in women), selerodermatous patches of the skin,
pink to blue coloration in the periorbital areas,
conjunctival injection, fragility of the skin of the
dorsum of the hands, melanosis (even in areas
not exposed to natural or artificial light), rapid
graying of the hair, occasionally darkening of
the hair, red urine (during flares of the disease or
following alcohol ingestion), and hepatomegaly.
The biochemical abnormalities to be found in-
clude elevated urine uroporphyrin and copro-
porphyrin, elevated feeal uroporphyrin and
corporphyrin, increased BSP values, and he-
patie cirrhosis. Abnormal glucose metabolism
(8), elevated serum iron and increased
transferritin saturation (7), and polyeythemia
(7) may also be found.
Clinical Features
Three patients with proven PCT were ad-
mitted to the Barnard Free Skin and Cancer
Hospital. Their ages were 53 to 68 years. One
male and two females are included: The man
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was an admitted heavy drinker, one woman a
social drinker, and the other a relative non-
drinker. Careful history failed to reveal signs
or symptoms of AlP.
Case No. 1.—This 68-year-old white female
first noted the occasional appearance of orange
to red urine, a pinkish-purple discoloration
about the eyes, and a "dirtiness" on the sides
of the neck approximately one year prior to
admission. Six months later she discovered in-
creased amounts of hair on the sides of her
face and 3 months prior to admission while
vacationing in Mexico, she developed the first
episode of vesieles and blisters on the dorsa of
both hands following sun exposure. Upon re-
turning home, a dermatologist diagnosed this
as PCT, and found markedly elevated urine
uroporphyrins and eoproporphyrins. The pa-
tient admitted to occasionally drinking a cock-
tail.
Past history included a fracture to thoracic
vertebrae 9 and 11 in 1964. Her previous
medications were digitalis, thyroid 1 grain
per day, and a diuretic. The patient had also
been taking estrogens for osteoporosis, but
these were discontinued after the diagnosis of
PCT was made.
Family history determined that none of her
4 siblings, 4 children, father or mother had
ever exhibited any similar symptoms.
Positive findings on physical examination
included purplish coloration in the periorbital
areas, hypertriehosis on both sides of face,
multiple eschars, milium and occasional blis-
ters on the dorsum of hands, multiple milia on
the back of the neck and melanosis of the back
of the neck extending down to the shoulders.
Multiple cherry hemangiomas were present on
the abdomen. The liver was palpable 3 to 4 em
below the right costal margin.
Case No. 2.—This 53-year-old white male
first noted episodic occurrences of red urine
approximately 4 to 5 years prior to admis-
sion. Two years ago the occurrence of vesieles
on dorsum of hands, precipitated by sunlight
and trauma was noted. At that time a derma-
tologist made the diagnosis of PCT. Since
then, the patient was treated with EDTA and
antihistamines with little or no change in
symptoms. He denied any other symptoms re-
ferable to PCT but complained of polydipsia
and polyuria. None of the parents or children
has any similar symptoms.
Past history was unremarkable except for
alcohol intake of about a quart of whiskey per
day. There has been only occasional beer in-
gestion in the past two years.
Physical examination of the skin revealed
several vesicles, esehars, and milia on the dor-
sum of the hands. The periorbital area
showed a pink to purple color. The skin of the
neck exhibited a furrowed and wrinkled ap-
pearance. The liver was palpable 5 to 6 em be-
low the right costal margin with a slightly
tender edge.
Case No. 3.—This 53-year-old white female
was entirely well until 6 months prior to ad-
mission when she first noted small, erythema-
tous macules on the dorsa of her hands. These
lesions progressed to large vesieles and bullae
when exposed to the sun. At the same time
she also noted a bluish coloration beneath both
eyes, long hairs on the face, arms, and thighs,
rapid graying of her hair and was informed
by others that her eyes were "bloodshot". She
had noted that her urine became red on 3 oc-
casions after drinking a glass of beer. This
amounted to her usual consumption of alcohol
each year. The patient denied abdominal pain,
but admitted to polydipsia, polyphagia, and
polyuria. She had ungergone an abdominal
laparotomy in 1945 for removal of a tubal
pregnancy. None of her parents or siblings has
ever exhibited similar symptoms. She had no
children.
Physical examination of the skin revealed
many freckles. There was increased pigmenta-
tion of the face, collar area, and upper arms, a
bluish-purple color around the eyes, hypertri-
ehosis of the sides of the face and posterior
aspect of the thighs, and graying of the scalp
and pubic hair. Many small vesioles and
milia were present on the dorsa of the hands
and forearms. Several esehars were noted on
the knuckle pads. The eonjunetivae were quite
injected and the liver was palpable 4 to 5 em
below the right eostal margin.
METHODS
Each patient was admitted to the metabolic
clinical research center unit for 3 to 4 weeks aad
placed on a routine diet, permitted access to the
rest of the hospital and exposure to sunlight if
they so desired. Alcoholic beverages were inter-
dicted. Prior to the test period, base line studies
of the skin status, hepatic function, and porphyrin
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excretory products were obtained. These were as-
sessed as follows:
Skin status: The presence or absence of vesicles,
their locations and fluorescence of vesicles, using
a Woods Lamp (3650 A) were noted. Other
cutaneous stigmata of PCT were recorded.
ilepatie function: Liver function tests including
BSP (45 mm), total protein with A/G ratio, serum
electrophoresis, alkaline phosphatase, cephalin floc-
culation, thymol turbidity, serum glutamic oxala-
cetic transaminase, serum glutamic pyruvic trans-
aminase, lactic acid dehydrogenase, and lactic acid
dehydrogeuase with heat, prothrombin time, radio-
active liver scan, and percutaneous liver biopsy
for fluorescence of the fresh liver specimen ob-
tained (positive in cases 2 and 3).
Porphyrin metabolism: Twenty-four hour urine
uroporphyrin and coproporphyrin excretion for
two days and 24-hour fecal uroporphyrin, copro-
porphyrin, and protoporphyrin for two days (Case
No. 1) were collected (porphyrin determinations
were performed by Bioscience Laboratories, Cali-
fornia, and Dr. John Vavra, Washington Uni-
versity, St. Louis).
Additional studies: Cryoglobulins, creatinine
phosphokinase, serum iron and iron blinding ca-
pacity, glucose tolerance tests, complete blood
count, platelets, and urinalysis. Serum levels of
griseofulvin were determined spectrophotofluoro-
metrically using the method of Bedford, Child,
and Tomich (23).
When these studies were completed, each pa-
tient was given a ten-day course of microsized
griseofulvin, 250 mg twice daily. The liver and
porphyrin studies were repeated every other day
for the entire test period.
REsULTs
Serum levels of griseofulvin were found to
be in the normal therapeutic range in all pa-
tients during the test period. Skin: While
griseofulvin was administered, those vesicles
present and undergoing healing were either
completely or partially healed by the end of the
study. At no time was there a recrudescence
or the appearance of new lesions. The more
permanent features (e.g. hirsutism and milia)
were unchanged. Vesieles present before and
during the test period did not demonstrate
fluorescence with the Wood lamp.
He patio Function
Base line liver studies (See Table I) re-
vealed the following: the BSP was abnormal in
all three eases, ranging from 10.7 mg per cent
to 13.3 mg per cent in 45 minutes; the liver
biopsies exhibited fatty metamorphosis (Case
No. 2) and cholestasis (canicular) (Case No.
3). In both cases fatty metamorphosis and
portal fibrosis were present and were inter-
preted as consistent with early cirrhosis. The
fresh liver tissue obtained in Cases No. 2 and
No. 3 demonstrated a characteristic red-pink
fluorescence under the Wood lamp. Radioac-
tive liver scans failed to reveal any evidence of
tumor.
During the period of griseofulvin therapy,
liver function tests were repeated every other
day. As can be seen in Table I, the BSP values
fluctuated from abnormal to normal and gener-
ally did not vary significantly from pre-thcr-
apy values (Fig. 1). All other liver tests were
within the normal range or consistent with
daily changes inasmuch as they showed mini-
mal variation.
Porphyrin metabolism: Complete nrine and
stool studies were obtained only in Case No.
1. The stool collections were not decided upon
until later in the study and then these collec-
tions presented difficulties both in patient
habits and in the preservation of the speci-
mens themselves.
The urine and stool were collected every
other day, and the values obtained arc re-
corded in Table II. There were no gross or sig-
nificant changes during the test period as com-
pared to pretreatment values.
The normal values obtained in Case No. 3
for urine uroporphyrin are not consistent and
are perhaps best explained by problems of
collection and storage procedures or laboratory
error.
Additional Studies
Cryoglobulins were negative in two patients
tested. Serum iron studies in one of two
patients studied revealed elevation of serum
iron to 227 mg/100 ml with a total iron
binding capacity of 333 mcg/100 ml or a
68% transferritin saturation. Glucose tolerance
tests demonstrated a diabetic type curve in
all three patients. The repeated hemograms,
although varying somewhat, showed no marked
changes, and the differential white blood
counts at no time showed a shift to the left.
Platelet counts were also obtained every two
days and were always within normal limits.
Routine urinalysis failed to demonstrate any
abnormalities. Serum eleotrophoresis was
within normal limits. Creatinine phospho-
kinase never exceeded normal limits.
DISCUSSION
These findings give evidence that when
griseofulvin is administered to PCT patients
in the usual therapeutic amounts clinical or
biochemical exacerbations of the disease are
not provoked.
The studies of DeMatteis and Rimington,
Weston Hurst and Paget, and others have
shown that griseofulvin will induce changes
in animals leading to excretion of increased
amounts of porphyrins (1, 3). Rimington,
in studying a group of 50 patients receiving
griseofulvin for tinea infection of the nails,
found elevations of coproporphyrin and proto-
porphyrin in a large percentage of cases (6).
However, the additional finding of eleva-
tion of total fecal porphyrins in tinea in-
fected but untreated patients was inexplicable.
Ziprkowski et al. reported on the effects of
griseofulvin in a PCT patient but with
findings somewhat different than those pre-
sented above (5). We are in agreement in
the lack of exacerbations of clinical symptoms
and biochemical findings to suggest a change
in liver function; however, he noted an in-
crease of fecal coproporphyrins while his pa-
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TABLE I
Hepatic Function
Normal
Pt. 1:11. G.
Control
Day 1
Day 3
Day 5
Day 7
Day 9
Day 1
(post-drug)
Pt. 2: J. D.
Control
Day 1
Day 3
Day 5
Day 7
Day 9
Day 1
(post-drug)
Pt. 3: H. B.
Control
Day 1
Day 3
Day 5
Day 7
1)ay 9
Day 1
(post-drug)
T. P.
6—8
7.0
7.5
6.0
7.5
6.8
6.5
6.9
8.0
6.9
7.6
7.0
7.1
6.8
6.7
7.1
7.1
7.1
7.1
6.6
7.2
A/G
4—5/2—3
4.1/2.9
4.2/3.3
3.7/2.3
4.6/2.9
3.9/2.9
4.0/2.5
3.6/3.3
4.2/3.8
4.6/2.8
4.0/3.6
3.8/3.2
4.0/3.1
3.7/3.1
3.9/2.8
4.1/3.0
4.6/2.5
4.4/2.7
4.5/2.6
4.1/2.5
4.6/2.6
Alk.
Phos.
4—12
(K. A.)
2.8
2.9
2.9
2.5
7.5
8.1
7.9
7.7
7.1
7.5
7.9
3.8
3.7
3.4
4.1
3.3
3.2
CPK
0-20
1
0
5
1
17
0
0
11
17
2
5
0
15
C. C.
Floc. +2
Trace
Trace
Neg.
+1
Trace
+1
Neg.
Neg.
Neg.
+3
Neg.
Neg.
+1
Neg.
Neg.
Neg.
Neg.
Neg.
Neg.
Neg.
Neg.
Protime
Control/Pt.
13.0/10.4
12 .9/10.3
12.7/11.1
12.1/9.2
12.8/10.7
12.2/10.8
13.2/10.9
T. T.
0—5
0.5
0.5
0.7
0.7
1.1
0.3
0.4
1.4
1.5
0.7
0.7
0.2
1.5
1.6
5.0
6.0
2.8
4.1
3.9
2.4
3.2
Bilirubin
Total
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
<0.8
SGOT/
SGPT
40/35
30/19
32/29
45/36
36/29
32/26
32/23
32/26
43/36
41/39
41/43
45/47
41/36
41/39
34/36
43/27
63/50
45/36
48/34
30/26
38/31
38/31
BSP 45
mm.
5—10
10.7
5.3
14.6
10.4
2.7
13.3
14.8
17.6
16.8
8.0
11.9
10.7
10.8
8.9
8.2
2.7
11.9
14.2
9.6
LDH/Heat
100—350/140
305/98
348/142
398/—
255/142
348/—
188/52
210/—
305/142
165/98
317/98
567/255
210/98
430/98
210/52
232/115
379/—
425/—
665/—
280/—
280/—
232/—
BSP CHANGES
6
6
DAYS Post-Drug
Foci. 1
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TABLE II
Porphyrin Determinations
Case Sample days
Urine Stool
Uroporphyrin Coproporphyrin Urn Copro Proto
1 Control 1,065 1,320 Neg. 1,800 1,440
It. G.
1
3
1,460
830
986
222
210
300
—
Neg.
Neg.
—
1,800
1,600
—
430
390
5
7
1,785
104
724
130
—
550
—
1,100
—
670
9
1 (post drug)
15
584
37
238
—
83
—
1,000
—
890
2 Control 5,540 174 — — —
J.D.
1
3
5
7
9
1 (post drug)
917
1,205
886
2,210
1,078
1,465
1,590
136
150
268
289
179
480
421
—
—
—
Neg.
—
—
—
—
—
—
2,100
—
—
—
—
—
—
610
—
—
—
3 Control 8,000 945 — — —
IT. B.
1
3
5
7
9
1(postdrug)
Normal micrograms/24 hr.
2,000
WNL
—
WNL
—
WNL
—
0—26
1,062
1,210
—
131
—
912
—
0—160
—
—
—
—
—
—
—
20—60
—.
—
—
—
—
—
—
400—1000
—
—
—
—
—
—
—
<300
tient was receiving griseofulvin with a sub-
sequent return to pretreatment levels when
the drug was discontinued.
The repeated liver function tests failed to
reveal any induced abnormalities. As can be
seen, these multiple tests do not show any
clinically significant change; the only test
showing any fluctuation was the BSP. In
these patients with PCT and cirrhosis (2
cases, biopsy proven) with its compromise
of liver function, the BSIP can be expected to
fluctuate daily. Waldenstrom in 1960, report-
ing on 14 cases of IPCT with multiple liver
function studies, found the BSP values to
fluctuate, and one of these cases maintained
an elevation of the BSP over a three-year
period despite a decrease in the urinary
uroporphyrin (10). Our BSP values were sub-
jected to statistical analysis for significance
of drug effect but, unfortunately, a valid con-
clusion could not be reached because of the
lack of a sufficient number of control BSP
values (Fig. 1).
The porphyrin determinations show vari-
ance, but in only a few instances is the
fluctuation to a higher degree than control
values. It was not demonstrated that porphyrin
excretion increases at any particular time in
the course of griseofulvin administration hut
it seemed to continue at its control level. If
anything, a decreased amount of porphyrin
in urine and stools can be found at the end
of the test period. It must be pointed out that
the control values exhibit wide swings in
daily excretion of porphyrins and thus may
account for reports of changes secondary to
griseofulvin and other agents. The association
of PCT and alcoholism is well documented
but two of our patients were definitely not
alcoholic and one of them was a relative
non-drinker.
The skin, as reported above, showed no
clinical exacerbation and, in fact, any yes-
ides present went on to complete clearing by
the end of the study.
The additional studies were initiated be-
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cause of reports of other abnormalities as-
sociated with PCT. The glucose tolerance tests
were performed as a result of the initial re-
ports of Sterling et al. (8), and others (7, 11)
showing a high correlation of diabetes with
FCT. Our studies are in agreement; however,
it should be mentioned that two of our three
patients were women, whereas diabetes and
PCT has been generally described in men.
Cryoglobulin studies in two cases were
negative. However, Biro et al. (13), reported
approximately 50 per cent positive results in
19 patients with FCT. Serum iron stndies,
as recorded above, are in agreement with the
work of Epstein (7), who has shown that
PCT can be associated with elevations of
serum iron and an increased saturation of
transferritin. The radioactive liver scans were
undertaken to exclude the rare possibility of
a liver cell adenoma as the cause of the PCT
symptoms complex, as reported by Tio et al.
(2).
It is of interest, but not unusual, that a
family history of similar symptoms could not
be obtained. Unfortunately, the opportunity
to study family members was lacking as these
patients came from distant areas.
5UMMAnY
Griseofulvin (500 mg/day mierosized) was
administered for a ten-day period to three
hospitalized patients with PCT. Skin status,
hepatic function, and porphyrin metabolism
were studied to detect any changes that might
have been induced. At no time was an exacer-
bation of the symptoms of PCT noted. No
changes other than those prior to the test
period were found in hepatie function and the
porphyrin determinations showed no clinically
significant changes that could imply a fiarenp
of PCT. These findings are in contrast to
reports of precipitation of PCT by griseo-
fulvin in laboratory animals.
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